Pharma

Your Article Summary

See Latest Articles

Roche to Commence Phase III Trials with Innovative Treatment Designed to Lower Cardiovascular Risk in Diabetes Patients with Recent Heart Attack
Roche, 06/10/09

Roche today announced it will start Phase III clinical investigations for aleglitazar, its innovative PPAR co-agonist R1439 which is uniquely designed to reduce cardiovascular morbidity and mortality in high risk patients with type 2 diabetes. This decision is supported by data from the Phase II SYNCHRONY study published today in The Lancet1 and announced at the American Diabetes Association meeting in New Orleans.

Today in Drug Trials...keeping you current

Receive free subspecialty "5-minute updates" via email

Bayer Starts Phase III Trial with Florbetaben
BayNews International, 12/01/09

Bioequivalence of two film-coated tablets of imatinib mesylate 400 mg: A randomized, open-label, single-dose, fasting, two-period, two-sequence crossover comparison in healthy male South American volunteers
Clinical Therapeutics, 12/01/09

Directly observed antiretroviral therapy: a systematic review and meta-analysis of randomised clinical trials
The Lancet - Early Online Publication, 12/01/09

 See all of Drug Trials